SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11) - Retz, Margitta; Teber, Dogu (European journal of cancer, 2019)
Available online 7 December 2018